Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Disruptive Pharma
- Target Recruit Count
- 12
- Registration Number
- NCT06797427
- Locations
- 🇸🇪
Clinical Trial Consultants (CTC), Dag Hammarskjölds väg 10B, Uppsala, Sweden
IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT06765005
- Locations
- 🇨🇳
Hangzhou First People's Hospital;, Hangzhou, Zhejiang, China
Combination of Toripalimab and JS004 Therapy for ccRCC
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT06690697
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
- Conditions
- Acute Myeloid Leukemia, in RelapseMyelodysplastic SyndromesChronic Myeloid LeukemiaMyeloproliferative Neoplasm
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 88
- Registration Number
- NCT06532084
- Locations
- 🇷🇺
RM Gorbacheva Research Institute, Saint Petersburg, Russian Federation
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 150
- Registration Number
- NCT06527495
- Locations
- 🇪🇬
NLI, Shibīn Al Kawm, Menoufia, Egypt
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
- Conditions
- Locally Advanced Thyroid Gland Carcinoma
- Interventions
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT06482086
- Locations
- 🇨🇳
West China hospital, Chengdu, Sichuan, China
A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating with Decitabine in Pediatric Relapsed and Refractory Acute Leukemias
- Conditions
- Refractory Acute LeukemiaRelapsed Acute Leukemia
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06474663
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase 2 Study of WGI-0301 for Advanced HCC
- Conditions
- Advanced Hepatocellular Carcinoma (HCC)
- Interventions
- Drug: WGI-0301 at MTD/RP2D dose IV infusion, QWDrug: WGI-0301 at MTD/RP2D -1 dose IV infusion, QW
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Zhejiang Haichang Biotech Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06309485
Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Second Xiangya Hospital of Central South University
- Target Recruit Count
- 10
- Registration Number
- NCT06227221
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
- Conditions
- AML, ChildhoodAcute Myeloid Leukemia
- Interventions
- Drug: Recombinant Human Granulocyte Colony-Stimulating Factor
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Children's Hospital of Soochow University
- Target Recruit Count
- 500
- Registration Number
- NCT06221683
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳XiangYa Hospital Central South University, Changsha, Hunan, China
🇨🇳Children's Hospital of Soochow University, Suzhou, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.